Interleukin-4 production in asthmatic patients during allergen immunotherapy: A preliminary study

Shahid Sheikh, Nanjundaiah Kumar, Myron Zitt, Dennis Bouboulis, Soo Fang Wang, Savita G Pahwa, Marianne Frieri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Chronic inflammation and cytokine amplification play a major role in the pathogenesis of asthma. Allergen immunotherapy in atopic asthma has been shown to be effective, but the precise immunologic mechanisms for clinical improvement are poorly understood. CD4+T-cells from atopic asthmatics produce increased levels of the cytokines such as interleukin-4 (IL-4), compared with CD4+T-cells from nonatopic nonasthmatic individuals and these cytokines are believed to be directly involved in allergic disease process. It is not clear if IL-4 secretion patterns change during immunotherapy. Objectives: Monitoring IL-4 levels may be very useful in evaluating the effectiveness and response to allergen immunotherapy. Methods: Peripheral blood mononuclear cells were obtained from healthy nonasthmatic controls (n = 5) and from atopic asthmatic patients (n = 5) prior to immunotherapy and at 3 and 6 months after initiation of immunotherapy to monitor IL-4 secretion in unstimulated and grass allergen-specific stimulated mononuclear cells. Changes in IL-4 secretions were related to clinical response to immunotherapy. Results: Mean IL-4 secretion was lower in controls than in asthmatics but the difference was not statistically significant. In asthmatics 3 months after starting immunotherapy mean IL-4 secretion significantly decreased (p < .002) in both grass antigen-specific stimulated cultures and un-stimulated cells. This pattern persisted at 6 months. Conclusion: In atopic asthmatics mean IL-4 secretion was significantly decreased during immunotherapy however this change was not allergen-stimulation dependent at the dose response chosen.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalPediatric Asthma, Allergy and Immunology
Volume11
Issue number1
StatePublished - Jul 24 1997
Externally publishedYes

Fingerprint

Immunologic Desensitization
Interleukin-4
Immunotherapy
Cytokines
Poaceae
Allergens
Asthma
T-Lymphocytes
Blood Cells
Inflammation
Antigens

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pediatrics, Perinatology, and Child Health

Cite this

Interleukin-4 production in asthmatic patients during allergen immunotherapy : A preliminary study. / Sheikh, Shahid; Kumar, Nanjundaiah; Zitt, Myron; Bouboulis, Dennis; Wang, Soo Fang; Pahwa, Savita G; Frieri, Marianne.

In: Pediatric Asthma, Allergy and Immunology, Vol. 11, No. 1, 24.07.1997, p. 17-22.

Research output: Contribution to journalArticle

Sheikh, S, Kumar, N, Zitt, M, Bouboulis, D, Wang, SF, Pahwa, SG & Frieri, M 1997, 'Interleukin-4 production in asthmatic patients during allergen immunotherapy: A preliminary study', Pediatric Asthma, Allergy and Immunology, vol. 11, no. 1, pp. 17-22.
Sheikh, Shahid ; Kumar, Nanjundaiah ; Zitt, Myron ; Bouboulis, Dennis ; Wang, Soo Fang ; Pahwa, Savita G ; Frieri, Marianne. / Interleukin-4 production in asthmatic patients during allergen immunotherapy : A preliminary study. In: Pediatric Asthma, Allergy and Immunology. 1997 ; Vol. 11, No. 1. pp. 17-22.
@article{c42b03c8ebd341af90dcc50373b92cff,
title = "Interleukin-4 production in asthmatic patients during allergen immunotherapy: A preliminary study",
abstract = "Background: Chronic inflammation and cytokine amplification play a major role in the pathogenesis of asthma. Allergen immunotherapy in atopic asthma has been shown to be effective, but the precise immunologic mechanisms for clinical improvement are poorly understood. CD4+T-cells from atopic asthmatics produce increased levels of the cytokines such as interleukin-4 (IL-4), compared with CD4+T-cells from nonatopic nonasthmatic individuals and these cytokines are believed to be directly involved in allergic disease process. It is not clear if IL-4 secretion patterns change during immunotherapy. Objectives: Monitoring IL-4 levels may be very useful in evaluating the effectiveness and response to allergen immunotherapy. Methods: Peripheral blood mononuclear cells were obtained from healthy nonasthmatic controls (n = 5) and from atopic asthmatic patients (n = 5) prior to immunotherapy and at 3 and 6 months after initiation of immunotherapy to monitor IL-4 secretion in unstimulated and grass allergen-specific stimulated mononuclear cells. Changes in IL-4 secretions were related to clinical response to immunotherapy. Results: Mean IL-4 secretion was lower in controls than in asthmatics but the difference was not statistically significant. In asthmatics 3 months after starting immunotherapy mean IL-4 secretion significantly decreased (p < .002) in both grass antigen-specific stimulated cultures and un-stimulated cells. This pattern persisted at 6 months. Conclusion: In atopic asthmatics mean IL-4 secretion was significantly decreased during immunotherapy however this change was not allergen-stimulation dependent at the dose response chosen.",
author = "Shahid Sheikh and Nanjundaiah Kumar and Myron Zitt and Dennis Bouboulis and Wang, {Soo Fang} and Pahwa, {Savita G} and Marianne Frieri",
year = "1997",
month = "7",
day = "24",
language = "English",
volume = "11",
pages = "17--22",
journal = "Pediatric, Allergy, Immunology, and Pulmonology",
issn = "2151-321X",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Interleukin-4 production in asthmatic patients during allergen immunotherapy

T2 - A preliminary study

AU - Sheikh, Shahid

AU - Kumar, Nanjundaiah

AU - Zitt, Myron

AU - Bouboulis, Dennis

AU - Wang, Soo Fang

AU - Pahwa, Savita G

AU - Frieri, Marianne

PY - 1997/7/24

Y1 - 1997/7/24

N2 - Background: Chronic inflammation and cytokine amplification play a major role in the pathogenesis of asthma. Allergen immunotherapy in atopic asthma has been shown to be effective, but the precise immunologic mechanisms for clinical improvement are poorly understood. CD4+T-cells from atopic asthmatics produce increased levels of the cytokines such as interleukin-4 (IL-4), compared with CD4+T-cells from nonatopic nonasthmatic individuals and these cytokines are believed to be directly involved in allergic disease process. It is not clear if IL-4 secretion patterns change during immunotherapy. Objectives: Monitoring IL-4 levels may be very useful in evaluating the effectiveness and response to allergen immunotherapy. Methods: Peripheral blood mononuclear cells were obtained from healthy nonasthmatic controls (n = 5) and from atopic asthmatic patients (n = 5) prior to immunotherapy and at 3 and 6 months after initiation of immunotherapy to monitor IL-4 secretion in unstimulated and grass allergen-specific stimulated mononuclear cells. Changes in IL-4 secretions were related to clinical response to immunotherapy. Results: Mean IL-4 secretion was lower in controls than in asthmatics but the difference was not statistically significant. In asthmatics 3 months after starting immunotherapy mean IL-4 secretion significantly decreased (p < .002) in both grass antigen-specific stimulated cultures and un-stimulated cells. This pattern persisted at 6 months. Conclusion: In atopic asthmatics mean IL-4 secretion was significantly decreased during immunotherapy however this change was not allergen-stimulation dependent at the dose response chosen.

AB - Background: Chronic inflammation and cytokine amplification play a major role in the pathogenesis of asthma. Allergen immunotherapy in atopic asthma has been shown to be effective, but the precise immunologic mechanisms for clinical improvement are poorly understood. CD4+T-cells from atopic asthmatics produce increased levels of the cytokines such as interleukin-4 (IL-4), compared with CD4+T-cells from nonatopic nonasthmatic individuals and these cytokines are believed to be directly involved in allergic disease process. It is not clear if IL-4 secretion patterns change during immunotherapy. Objectives: Monitoring IL-4 levels may be very useful in evaluating the effectiveness and response to allergen immunotherapy. Methods: Peripheral blood mononuclear cells were obtained from healthy nonasthmatic controls (n = 5) and from atopic asthmatic patients (n = 5) prior to immunotherapy and at 3 and 6 months after initiation of immunotherapy to monitor IL-4 secretion in unstimulated and grass allergen-specific stimulated mononuclear cells. Changes in IL-4 secretions were related to clinical response to immunotherapy. Results: Mean IL-4 secretion was lower in controls than in asthmatics but the difference was not statistically significant. In asthmatics 3 months after starting immunotherapy mean IL-4 secretion significantly decreased (p < .002) in both grass antigen-specific stimulated cultures and un-stimulated cells. This pattern persisted at 6 months. Conclusion: In atopic asthmatics mean IL-4 secretion was significantly decreased during immunotherapy however this change was not allergen-stimulation dependent at the dose response chosen.

UR - http://www.scopus.com/inward/record.url?scp=0030763134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030763134&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030763134

VL - 11

SP - 17

EP - 22

JO - Pediatric, Allergy, Immunology, and Pulmonology

JF - Pediatric, Allergy, Immunology, and Pulmonology

SN - 2151-321X

IS - 1

ER -